Harada T, Kan N, Okino T, Ichinose Y, Moriguchi Y, Li L, Sugie T, Ohgaki K, Imamura M
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Surg Today. 1994;24(6):561-3. doi: 10.1007/BF01884580.
BALB/c mice were pretreated intraperitoneally with interleukin-1 (IL-1) and sonicated tumor extract (SE) from plasmacytoma MOPC104E, 10, 7, and 4 days prior to the intraperitoneal or subcutaneous inoculation of MOPC104E cells, following which significant suppression was observed. The mean survival time and tumor diameter on day 21 were 46.7 days and 0 mm, respectively, in contrast to the 20.9 days and 20.4 mm of control mice. Mice pretreated with IL-1 and SE from MOPC104E (MOPC-SE) were not suppressed following fibrosarcoma MethA inoculation, which indicates the tumor specificity of immunity in this model. This systemically operating antitumor immunity was also achieved by the intramuscular administration of IL-1, or when tumor challenge was performed on day 7 or 14. Moreover, MOPC104E-specific delayed-type hypersensitivity was detected in these mice. The results of this study suggest the possibilities of a new type of active specific immunotherapy, which could prove useful as postsurgical adjuvant therapy for cancer patients.
在腹腔或皮下接种浆细胞瘤MOPC104E细胞前10天、7天和4天，给BALB/c小鼠腹腔注射白细胞介素-1（IL-1）和来自浆细胞瘤MOPC104E的超声破碎肿瘤提取物（SE）进行预处理，随后观察到显著的抑制作用。与对照小鼠的20.9天和20.4毫米相比，第21天的平均存活时间和肿瘤直径分别为46.7天和0毫米。用来自MOPC104E的IL-1和SE（MOPC-SE）预处理的小鼠在接种纤维肉瘤MethA后未受到抑制，这表明该模型中免疫具有肿瘤特异性。通过肌肉注射IL-1，或在第7天或第14天进行肿瘤攻击时，也可实现这种全身作用的抗肿瘤免疫。此外，在这些小鼠中检测到了MOPC104E特异性迟发型超敏反应。本研究结果提示了新型主动特异性免疫疗法的可能性，这可能作为癌症患者术后辅助治疗是有用的。
